Trial results

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

NCT02049034 on ClinicalTrials.gov · last registry update 2024-12-16

A small phase 4 — 8 participants, against a typical 72. The sponsor logged completion for January 2016. Primary outcome, as filed: Postprandial glucose kinetics. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

University of Surrey

Sponsor type

Other

Enrollment

8

Started

2014-01

Primary completion

2016-01 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Postprandial glucose kinetics

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.